{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:04:36Z","timestamp":1784653476037,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10096-019-03611-1","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T06:02:58Z","timestamp":1560405778000},"page":"1773-1780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The association between fluconazole dose and MIC with mortality and persistence in candidemia"],"prefix":"10.1007","volume":"38","author":[{"given":"Nesrin","family":"Ghanem-Zoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Qasum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johad","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Zorbavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Arnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Geffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"3611_CR1","unstructured":"Clinical and laboratory standards institute reference method for broth dilution antifungal susceptibility testing of yeasts: Fourth informational supplement M27-S4. Wayne, PA: USACLSI; 2012"},{"key":"3611_CR2","doi-asserted-by":"crossref","unstructured":"Koga-Ito CY, Lyon JP, de Resende MA Comparison between E-test and CLSI broth microdilution method for antifungal susceptibility testing of Candida albicans oral isolates. Rev Inst Med Trop Sao Paulo [cited 2019 7];50:7\u201310. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18327480","DOI":"10.1590\/S0036-46652008000100002"},{"key":"3611_CR3","doi-asserted-by":"publisher","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al (2015) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis [cited 2019 2];62:civ933. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26679628\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1093\/cid\/civ933","DOI":"10.1093\/cid\/civ933"},{"key":"3611_CR4","unstructured":"Fluconazole rationale for the EUCAST clinical breakpoints, version 2.0. 2013 [cited 2019 24]. \n                    http:\/\/www.eucast.org"},{"key":"3611_CR5","unstructured":"European committee on antimicrobial susceptibility testing antifungal agents. Breakpoint tables for interpretation of MICs. Version 7.0. 2014;0\u20134"},{"key":"3611_CR6","doi-asserted-by":"publisher","unstructured":"Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH (2005) Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother [cited 2018 19];49:3171\u20137. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16048920\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1128\/AAC.49.8.3171-3177.2005","DOI":"10.1128\/AAC.49.8.3171-3177.2005"},{"key":"3611_CR7","doi-asserted-by":"publisher","unstructured":"Pai MP, Turpin RS, Garey KW (2007) Association of fluconazole area under the concentration-time curve\/mic and dose\/mic ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1 [cited 2018 18];51:35\u20139. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17101684\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1128\/AAC.00474-06","DOI":"10.1128\/AAC.00474-06"},{"key":"3611_CR8","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Tudela JL, Almirante B, Rodr\u00edguez-Pardo D, Laguna F, Donnelly JP, Mouton JW, et al (2007) Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother [cited 2018 19];51:3599\u2013604. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17646421\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1128\/AAC.00296-07","DOI":"10.1128\/AAC.00296-07"},{"key":"3611_CR9","doi-asserted-by":"publisher","unstructured":"Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR (2008) Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother [cited 2018 19];52:3022\u20133028. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18591269\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1128\/AAC.00116-08","DOI":"10.1128\/AAC.00116-08"},{"key":"3611_CR10","doi-asserted-by":"publisher","unstructured":"Brosh-Nissimov T, Ben-Ami R (2015) Differential association of fluconazole dose and dose\/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection. Clin Microbiol Infect [cited 2018 19]; 21:1011\u20131017. \n                    https:\/\/doi.org\/10.1016\/j.cmi.2015.07.005\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1016\/j.cmi.2015.07.005","DOI":"10.1016\/j.cmi.2015.07.005"},{"key":"3611_CR11","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Ruiz M, Guinea J, Lora-Pablos D, Zaragoza \u00d3, Puig-Asensio M, Almirante B, et al (2017) Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. Clin Microbiol Infect [cited 2018 19];23:672.e1\u2013672.e11. \n                    https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1198743X17300472?via%3Dihub\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1016\/J.CMI.2017.01.014","DOI":"10.1016\/J.CMI.2017.01.014"},{"key":"3611_CR12","doi-asserted-by":"publisher","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al (2017) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem [cited 2019 30];53:766\u201372. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17332152\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1373\/clinchem.2006.077180","DOI":"10.1373\/clinchem.2006.077180"},{"key":"3611_CR13","doi-asserted-by":"publisher","unstructured":"Sobue S, Tan K, Layton G, Leclerc V, Weil A (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol [cited 2019 30];57:773\u2013784. \n                    http:\/\/doi.wiley.com\/10.1111\/j.1365-2125.2004.02073.x\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02073.x","DOI":"10.1111\/j.1365-2125.2004.02073.x"},{"key":"3611_CR14","doi-asserted-by":"publisher","unstructured":"Siqueira RA, Doi AM, de Petrus Crossara PP, Koga PCM, Marques AG, Nunes FG, et al (2018) Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2\u00ae and Sensititre YeastOne\u00ae. Rev Iberoam Micol [cited 2019 7];35:83\u20137. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29580699\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1016\/j.riam.2017.11.001","DOI":"10.1016\/j.riam.2017.11.001"},{"key":"3611_CR15","doi-asserted-by":"publisher","unstructured":"Pfaller MA, Diekema DJ, Sheehan DJ (2006) Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev [cited 2019 9];19:435\u201347. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16614256\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.1128\/CMR.19.2.435-447.2006","DOI":"10.1128\/CMR.19.2.435-447.2006"},{"key":"3611_CR16","doi-asserted-by":"publisher","unstructured":"Kaur R, Dhakad M, Goyal R, Haque A, Mukhopadhyay G (2016) Identification and antifungal susceptibility testing of Candida species: a comparison of Vitek-2 system with conventional and molecular methods. J Glob Infect Dis [cited 2019 7];8:139. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27942193\n                    \n                  \n                           \n                    https:\/\/doi.org\/10.4103\/0974-777X.192969","DOI":"10.4103\/0974-777X.192969"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03611-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T12:28:26Z","timestamp":1565872106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03611-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03611-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"24 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee at Rambam Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required; not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}